Keywords: بقای آزاد شدن پیشرفت; Endometrial stromal sarcoma; Progression free survival; Adjuvant therapy; Oophorectomy; Hormonal suppression;
مقالات ISI بقای آزاد شدن پیشرفت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بقای آزاد شدن پیشرفت; GEP; gene expression profiling; PFS; progression free survival; DRP; drug response prediction; TT; Total therapy; IMWG; The International Myeloma Work Group; ASCT; autologous stem cell transplantation; MMSET-high; high expression levels of MMSET; MAF-high
Keywords: بقای آزاد شدن پیشرفت; BACE; bronchial arterial chemoembolization; CBM; China biological medicine database; CNKI; China national knowledge infrastructure database; CENTRAL; Cochrane Central Register of Controlled Trials; Chi-CTR; Chinese clinical trial registry; DCR; disease co
Keywords: بقای آزاد شدن پیشرفت; NSCLC; non-small cell lung cancer; RCTs; randomized controlled trials; OS; overall survival; PFS; progression free survival; ORR; objective response rate; AEs; adverse effects; HR; hazard ratio; RR; relative risk; CI; confidence intervals; FDA; Food and D
Keywords: بقای آزاد شدن پیشرفت; aBCC; advanced basal cell carcinoma; AE; adverse event; PI3K; phosphoinositide-3-kinase; PFS; progression free survival; SI; smoothened inhibitor;
Keywords: بقای آزاد شدن پیشرفت; ALK; Anaplastic Lymphoma Kinase; CI; Confidence interval; CT; Computerized Tomography; EGFR; Epidermal Growth Factor Receptor; ESMO; European Society of Medical Oncology; 18F-FDG; Fluorodeoxyglucose; IQR; Interquartile range; MATV; Metabolic Active Tumor
Keywords: بقای آزاد شدن پیشرفت; Pancreatic adenocarcinoma; Resectable tumor; Laparotomy; Survival; PDAC; Pancreatic ductal adenocarcinoma; OS; overall survival; PFS; progression free survival; DFS; disease free survival; SMV; Superior mesenteric vein; SMA; Superior mesenteric artery; PV
Keywords: بقای آزاد شدن پیشرفت; 5mC; 5- hydroxymethylcytosine; AML; acute myeloid leukemia; BET; bromodomain inhibitors; CCOC; clear cell ovarian cancer; ctDNA; cell-free tumor DNA; ChIP-on-chip; chromatin immunoprecipitation with DNA microarray; CIMP; CpG island methylator phenotype; C
Keywords: بقای آزاد شدن پیشرفت; ALA; 5-aminolevulinic acid; BM; Brain metastasis; CT; Computerized tomographic; DFI; Disease free interval; EoR; Extent of resection; FDG; Fludeoxyglucose (18F); IONM; intra-operative neurophysiologic monitoring; KPS; Karnofsky performance score; MRI; Mag
Keywords: بقای آزاد شدن پیشرفت; AUC; area under the ROC curve; CCA; cholangiocarcinoma; EAC; esophageal adenocarcinoma; ESCC; Esophageal squamous cell carcinoma; FDA; US Food and Drug Administration; FIT; fecal immunochemical test; FOBT; fecal occult blood test; GI; gastrointestinal; HC
Keywords: بقای آزاد شدن پیشرفت; Analysis of survival; CML; Event free survival; Overall survival; Progression free survival;
Keywords: بقای آزاد شدن پیشرفت; Glioblastoma; Lactate; Overall survival; Progression free survival;
Keywords: بقای آزاد شدن پیشرفت; Hgb; hemoglobin; NLR; neutrophil-to-lymphocyte ratio; CRT; chemoradiotherapy; EBRT; external beam radiotherapy; BT; brachytherapy; WBC; white blood cell; Plt; platelet; PFS; progression free survival; OS; overall survival; AOTHgb; average on treatment hem
Keywords: بقای آزاد شدن پیشرفت; Pituitary adenoma; Long term follow up; Progression free survival;
Keywords: بقای آزاد شدن پیشرفت; Metastatic breast cancer; Progression free survival; Overall survival; Surrogacy; Meta-analysis; ROC curve; Classification tree; Surrogate threshold effect;
Keywords: بقای آزاد شدن پیشرفت; AH/AL; heavy/light chain amyloidosis; AL; immunoglobulin light chain amyloidosis; ALL; localized immunoglobulin light chain amyloidosis; BSC; best supportive care; DMSO; dimethyl sulfoxide; IFE; immunofixation; MALT; mucosa-associated lymphoid tissue; MGU
Keywords: بقای آزاد شدن پیشرفت; ADCC; antibody-dependent cell-mediated cytotoxicity; AKT; protein kinase B; ATP; adenosine triphosphate; cfDNA; circulating free DNA; CISH; chromogenic in-situ hybridization; CTC; circulating tumor cells; EGFR; epithelial growth factor receptor; EMT; epit
Keywords: بقای آزاد شدن پیشرفت; AML; acute myeloid leukemia; CAK; CDK-activating kinase; CDK; cyclin-dependent kinases; CLL; chronic lymphocytic leukemia; CT; RNA polymerase II C-terminal domain; DLT; dose-limiting toxicities; DSIF; DRB-sensitivity inducing factor; ER; estrogen Receptor
Keywords: بقای آزاد شدن پیشرفت; kidney; carcinoma; renal cell; neoplasm metastasis; interleukin-2; molecular targeted therapy; CR; complete response; ECOG; Eastern Cooperative Oncology Group; HDIL-2; high dose IL-2; IL-2; interleukin-2; mRCC; metastatic RCC; OS; overall survival; PD; pr
Keywords: بقای آزاد شدن پیشرفت; ALT; alternative lengthening of telomeres; BP; base pair; CLL; chronic lymphatic leukemia; CSS; cancer specific survival; CI; Confidence interval; DFS; disease free survival; EFS; event free survival; FISH; fluorescent in situ hybridization; GEP-NET; gast
Keywords: بقای آزاد شدن پیشرفت; Patient-reported outcomes; Clinical trial endpoints; Progression free survival; Overall survival;
Keywords: بقای آزاد شدن پیشرفت; Meningioma; Long term follow up; Progression free survival
Keywords: بقای آزاد شدن پیشرفت; Pancreatic cancer; Angiogenesis; Vascular endothelial growth factor (VEGF); ANGPT; angiopoietin; BRAF; serine/threonine-protein kinase B-raf; CAF; cancer associated fibroblast; Cdkn2a; cyclin-dependent kinase inhibitor 2A; CI; confidence interval; CSF1R;
Keywords: بقای آزاد شدن پیشرفت; Overall survival; Progression free survival; Prognostic factors; Long-term follow up; Extended long-term follow-up
Keywords: بقای آزاد شدن پیشرفت; Breast cancer; Clinical trial; End-point; Progression free survival; Time to progression; Time to treatment failure
Keywords: بقای آزاد شدن پیشرفت; Anaplastic meningioma; Overall survival; Progression free survival; Radiotherapy; Recurrence
Keywords: بقای آزاد شدن پیشرفت; HD FSRT; high dose fractionated stereotactic photon radiation therapy; GTR; gross total resection; STR; sub total resection; PFS; progression free survival; Chordoma; High dose fractionated radiotherapy; Disease free survival;
Keywords: بقای آزاد شدن پیشرفت; Chemotherapy; Drug resistance; Metastatic breast cancer; Progression free survival; Response rate;
Keywords: بقای آزاد شدن پیشرفت; Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Keywords: بقای آزاد شدن پیشرفت; 18F-FAZA; 18F-labeled fluoroazomycin arabinoside; 18F-FDG; 18F-labeled fluorodeoxyglucose; 18F-FLT; 18F-labeled fluorothymidine; 18F-HX4; 18F-labeled flortanidazole; 18F-MISO; 18F-labeled fluoromisonidazole; 62Cu-ATSM; 62Cu-labeled diacetyl-bis(N-methylth
Keywords: بقای آزاد شدن پیشرفت; Breast cancer; Immune system; Biomarkers; Immunotherapies; Immune checkpoint blockade; Tumor vaccines; ADCC; antibody dependent cellular cytotoxicity; BiTES; bispecific single chain monoclonal antibodies; CAR; T cells engineered to express artificial chim
Keywords: بقای آزاد شدن پیشرفت; Meningioma; Radiosurgery; Progression free survival; Combined treatment
Keywords: بقای آزاد شدن پیشرفت; Drug approval; Progression free survival; Targeted therapy; Cytotoxic therapy; Clinical trials
Keywords: بقای آزاد شدن پیشرفت; 2 DE; 2-dimensional electrophoresis; ABPP; activity-based protein profiling; BFGF; basic fibroblast growth factor; CML; chronic myeloid leukemia; CRC; colorectal cancer; DIGE; differential in gel electrophoresis; EGF(R); epidermal growth factor (receptor)
Keywords: بقای آزاد شدن پیشرفت; EGFR-TKI; epidermal growth factor receptor tyrosine kinase inhibitor; MST; median survival time; HGF; hepatocyte growth factor; FISH; fluorescence in situ hybridization; PTEN; phosphatase and tensin homolog deleted from chromosome 10; PI3K; phosphoinositi
Keywords: بقای آزاد شدن پیشرفت; Ovarian cancer; Clinical trial endpoints; Progression free survival; Overall survival
Keywords: بقای آزاد شدن پیشرفت; Uterine cancer; Lymph nodes; Progression free survival;
Keywords: بقای آزاد شدن پیشرفت; Anti-angiogenesis; Resistance; Targeted therapies; Predictive markers; Autophagy; AKT/PKB; protein kinaseB; BMDCs; bone marrow-derived cells; BVZ; bevacizumab/Avastin; CSC; cancer stem-like cells; EGF; epidermal growth factor; EPC; endothelial progenitor
Solitary fibrous tumor/hemangiopericytoma expanding the superior and inferior cerebellar tentorium: A case report
Keywords: بقای آزاد شدن پیشرفت; CD; clusters of differentiation; CNS; central nervous system; CT; computed tomography; EMA; epithelial membrane antigen; GTR; Gross total resection; HPC; hemangiopericytoma; HPF; high-power fields; MRI; magnetic resonance imaging; OS; overall survival; PF
Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines
Keywords: بقای آزاد شدن پیشرفت; ADRs; adverse drug reactions; AMI; astragalus membranaceus injection; CNKI; China national knowledge infrastructure database; CBM; China biological medicine database; CR; complete response; CI; confidence interval; CTCAE 3.0; Common Terminology Criteria f
Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
Keywords: بقای آزاد شدن پیشرفت; Recurrent glioblastoma; Overall survival; Progression free survival; Reoperation; MGMT; Gross total resection;
Primary and metastatic malignancies of the lung: Retrospective analysis of the CT-guided high-dose rate brachytherapy (CT-HDRBT) ablation in tumours <4âcm and â¥4âcm
Keywords: بقای آزاد شدن پیشرفت; CT-HDRBT; CT-guided high dose rate brachytherapy; SBRT; stereotactic body radiotherapy; RFA; radiofrequency ablation; MWA; microwave ablation; LITT; laser induced thermotherapy; CTx; chemotherapy; RTx; radiation therapy; pLTC; primary local tumour control
Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients
Keywords: بقای آزاد شدن پیشرفت; Epithelial ovarian cancer (EOC); Ascitic fluid; Interleukin-6 (IL-6); Vascular endothelial growth factor (VEGF-A); Diagnostic bio-marker; Prognostic bio-marker; Progression free survival;
Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy
Keywords: بقای آزاد شدن پیشرفت; WR; Waldeyer's ring; NHL; non-Hodgkin's lymphoma; DLBCL; diffuse large B-cell lymphoma; RT; radiotherapy; IFRT; Involved field radiation therapy; CT; immunochemotherapy; PET-CT; positron emission tomography-computed tomography; DFS; disease free survi
Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
Keywords: بقای آزاد شدن پیشرفت; Head and neck cancer; Recurrent/metastatic; Anti-EGFR; Second line treatment; Progression-free survival; Gene expression signatures; Hypoxia signature; Microenvironment score; miRNA; EGFR; epidermal growth factor receptor; mAb; monoclonal antibody; RM; re
Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma
Keywords: بقای آزاد شدن پیشرفت; ANOVA; analysis of variance; ATF6; activating transcription factor 6; C/EBP; CAAT/enhancer binding protein; IRE1; inositol-requiring enzyme 1; CHOP/GADD153; C/EBP homologous protein/growth arrest/DNA damage inducible 153; CEA; carcino-embrionic antigen; C
Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies
Keywords: بقای آزاد شدن پیشرفت; ASCO; American Society of Clinical Oncology; BRAF; B-raf proto-oncogene, serine/threonine kinase; CTLA4; cytotoxic T-lymphocyte associated protein 4; ESMO; European Society for Medical Oncology; FDA; Food and Drug Administration; ICER; incremental cost-ef
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Keywords: بقای آزاد شدن پیشرفت; NNSCLC; non-small cell lung cancer; OS; overall survival; EGFR; epidermal growth factor receptor; TKI; tyrosine kinase inhibitor; ALK; Anaplastic lymphoma kinase; MET; mesenchymal epithelial transition factor; PFS; progression free survival; HER2; human e
Using microRNAs as Novel Predictors of Urologic Cancer Survival: An Integrated Analysis
Keywords: بقای آزاد شدن پیشرفت; miRNAs; Urologic cancer; Prognosis; Biomarker; Bioinformatics analysis; miRNA panel; RNA; ribonucleic acid; miRNA; microRNA; KCa; kidney cancer; BCa; bladder cancer; PCa; prostate cancer; TCGA; The Cancer Genome Atlas; OS; overall survival; PSA; prostate
A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients
Keywords: بقای آزاد شدن پیشرفت; 3β-HSD1; 3β-hydroxysteroid dehydrogenase/Î5â4 isomerase 1; CYP17A1; 17αâhydroxylase/17,20âlyase; Î4A; Î4-abiraterone; ABI; abiraterone; ADT; androgen-deprivation therapy; Cmin; mean of trough plasma concentrations measured during the first thr